A Randomized Trial of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine In The Treatment of Uncomplicated Malaria among Children in Western Kenya

Simple item page
dc.contributor.authorOnyango, Peter
dc.contributor.authorMcMorrow, Meredith
dc.contributor.authorOtieno, Kephas
dc.contributor.authorAgarwal, Aarti
dc.contributor.authorOdero, Christopher
dc.contributor.authorWilliamson, John
dc.contributor.authorKariuki, Simon
dc.contributor.authorKachur, Stephen Patrick
dc.contributor.authorSlutsker, Laurence
dc.contributor.authorDesai, Meghna
dc.date.accessioned2025-02-10T08:29:41Z
dc.date.available2025-02-10T08:29:41Z
dc.date.issued2013
dc.descriptionJournal Article
dc.description.abstractBackground: Artemether-lumefantrine (AL) was adopted as first-line treatment for uncomplicated malaria in Kenya in 2006. Monitoring drug efficacy at regular intervals is essential to prevent unnecessary morbidity and mortality. The efficacy of AL and dihydroartemisinin-piperaquine (DP) were evaluated for the treatment of uncomplicated malaria in children aged six to 59 months in western Kenya. Methods: From October 2010 to August 2011, children with fever or history of fever with uncomplicated Plasmodium falciparum mono-infection were enrolled in an in vivo efficacy trial in accordance with World Health Organization (WHO) guidelines. The children were randomized to treatment with a three-day course of AL or DP and efficacy outcomes were measured at 28 and 42 days after treatment initiation. Results: A total of 137 children were enrolled in each treatment arm. There were no early treatment failures and all children except one had cleared parasites by day 3. Polymerase chain reaction (PCR)-uncorrected adequate clinical and parasitological response rate (ACPR) was 61% in the AL arm and 83% in the DP arm at day 28 (p = 0.001). PCR-corrected ACPR at day 28 was 97% in the AL group and 99% in the DP group, and it was 96% in both arms at day 42. Conclusions: AL and DP remain efficacious for the treatment of uncomplicated malaria among children in western Kenya. The longer half-life of piperaquine relative to lumefantrine may provide a prophylactic effect, accounting for the lower rate of re-infection in the first 28 days after treatment in the DP arm.
dc.identifier.citationOnyango, P., McMorrow, M., Otieno, K., Agarwal, A., Odero, C., Williamson, J., Kariuki, S., Kachur, S. P., Slutsker, L., & Desai, M. (2013). A Randomized Trial of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine In The Treatment of Uncomplicated Malaria among Children in Western Kenya. Malaria Journal.
dc.identifier.urihttps://repository.daystar.ac.ke/handle/123456789/6229
dc.language.isoen
dc.publisherMalaria Journal
dc.relation.ispartofseries(12)254
dc.subjectArtemether-lumefantrine
dc.subjectDihydroartemisinin-piperaquine
dc.subjectUncomplicated malaria
dc.titleA Randomized Trial of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine In The Treatment of Uncomplicated Malaria among Children in Western Kenya
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
A Randomized Trial of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine In The Treatment of Uncomplicated Malaria among Children in Western Kenya.pdf
Size:
723.74 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal Articles